Page 1

Logo NEWS RELEASE Edwards Lifesciences Reports Second Quarter Results 7/29/2021 IRVINE , Calif . , July 29 , 2021 / PRNewswire / -- Edwards Lifesciences ( NYSE : EW ) today reported financial results for the quarter ended June 30 , 2021 . Second Quarter Highlights and 2021 Outlook • Sales rebounded and grew 49 percent to $ 1.4 billion ; underlying1 sales grew 44 percent • TAVR sales exceeded expectations and grew 52 percent ; underlying sales grew 48 percent • EPS was $ 0.78 ; adjusted1 EPS was $ 0.64 • Continued progress on five pivotal trials in TMTT • 2021 sales guidance raised to $ 5.2 to $ 5.4 billion from $ 4.9 to $ 5.3 billion • 2021 adjusted EPS guidance raised to the high end of previous $ 2.07 to $ 2.27 range " We were encouraged by the clear signs of recovery during the second quarter , " said Michael A. Mussallem , chairman and CEO . " Vaccine adoption in key regions has contributed to an increased number of patients seeking and , most importantly , receiving treatment . This quarter , we were pleased that more than 30,000 patients were treated globally with SAPIEN valves , an indication that more patients are benefiting from our life - changing technologies than ever before . " Second Quarter 2021 Results Sales for the quarter ended June 30 , 2021 , were $ 1.4 billion , up 49 percent over the prior year , or 44 percent on an underlying basis . Sales grew 11 percent on an underlying two - year compounded annual basis compared to the strong pre - pandemic second quarter of 2019. All four product groups delivered strong sales growth , led by TAVR . Diluted earnings per share for the quarter were $ 0.78 , while adjusted earnings per share were $ 0.64 . The company recorded a reduction in the fair value of its contingent liabilities , a $ 0.14 benefit that was excluded from adjusted earnings per share . Transcatheter Aortic Valve Replacement ( TAVR ) For the quarter , the company reported TAVR sales of $ 902 million , a year - over - year increase of 52 percent on a reported basis , or 48 percent on an underlying basis . Second quarter sales grew 14 percent on an underlying two year compounded annual basis . 1